Orexigen Therapeutics (NASDAQ:OREX) : During the past 4 weeks, traders have been relatively bearish on Orexigen Therapeutics (NASDAQ:OREX), hence the stock is down -6.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.06% relative to the S&P 500. The 4-week change in the price of the stock is -5.34% and the stock has fallen -0.8% in the past 1 week.
The company shares have dropped -90.70% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $4.92 and the one year low was seen on May 19, 2016. The 50-Day Moving Average price is $0.45 and the 200 Day Moving Average price is recorded at $0.90.
The stock has recorded a 20-day Moving Average of 2.73% and the 50-Day Moving Average is 2.2%.
Orexigen Therapeutics (NASDAQ:OREX): stock turned positive on Friday. Though the stock opened at $0.43, the bulls momentum made the stock top out at $0.4555 level for the day. The stock recorded a low of $0.4255 and closed the trading day at $0.445, in the green by 3.44%. The total traded volume for the day was 1,622,588. The stock had closed at $0.4302 in the previous days trading.
In an insider trading activity,The officer (Chief Commercial Officer) of Orexigen Therapeutics, Inc., Booth Mark D sold 50,000 shares at $5.68 on February 26, 2015. The Insider selling transaction had a total value worth of $284,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.